Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Sep;31(9):1323–1327. doi: 10.1128/aac.31.9.1323

Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection.

S F Queener 1, M S Bartlett 1, M A Jay 1, M M Durkin 1, J W Smith 1
PMCID: PMC174935  PMID: 2445281

Abstract

Trimetrexate and BW301U (piritrexim isethionate), lipid-soluble inhibitors of dihydrofolate reductase, are potent inhibitors of the growth of Pneumocystis carinii in culture with WI-38 cells. Inhibition was observed with 0.1 microgram of trimetrexate or BW301U per ml. Trimethoprim is ineffective at 100 micrograms/ml in this culture system. Both trimetrexate and BW301U were effective as prophylactic agents against P. carinii pneumonia in rats; trimetrexate at 7.5 mg/kg protected 9 of 10 rats, and BW301U at 5 mg/kg protected 4 of 10.

Full text

PDF
1323

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allegra C. J., Kovacs J. A., Drake J. C., Swan J. C., Chabner B. A., Masur H. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J Exp Med. 1987 Mar 1;165(3):926–931. doi: 10.1084/jem.165.3.926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bartlett M. S., Eichholtz R., Smith J. W. Antimicrobial susceptibility of Pneumocystis carinii in culture. Diagn Microbiol Infect Dis. 1985 Sep;3(5):381–387. doi: 10.1016/0732-8893(85)90076-8. [DOI] [PubMed] [Google Scholar]
  3. Bartlett M. S., Marr J. J., Queener S. F., Klein R. S., Smith J. W. Activity of inosine analogs against Pneumocystis carinii in culture. Antimicrob Agents Chemother. 1986 Jul;30(1):181–183. doi: 10.1128/aac.30.1.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bartlett M. S., Verbanac P. A., Smith J. W. Cultivation of Pneumocystis carinii with WI-38 cells. J Clin Microbiol. 1979 Dec;10(6):796–799. doi: 10.1128/jcm.10.6.796-799.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bertino J. R., Sawicki W. L., Moroson B. A., Cashmore A. R., Elslager E. F. 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (tmq), a potent non-classical folate antagonist inhibitor--I effect on dihydrofolate reductase and growth of rodent tumors in vitro and in vivo. Biochem Pharmacol. 1979 Jun 15;28(12):1983–1987. doi: 10.1016/0006-2952(79)90655-5. [DOI] [PubMed] [Google Scholar]
  6. Cushion M. T., Walzer P. D. Growth and serial passage of Pneumocystis carinii in the A549 cell line. Infect Immun. 1984 May;44(2):245–251. doi: 10.1128/iai.44.2.245-251.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Duch D. S., Edelstein M. P., Nichol C. A. Inhibition of histamine-metabolizing enzymes and elevation of histamine levels in tissues by lipid-soluble anticancer folate antagonists. Mol Pharmacol. 1980 Jul;18(1):100–104. [PubMed] [Google Scholar]
  8. Frenkel J. K., Good J. T., Shultz J. A. Latent Pneumocystis infection of rats, relapse, and chemotherapy. Lab Invest. 1966 Oct;15(10):1559–1577. [PubMed] [Google Scholar]
  9. Gordin F. M., Simon G. L., Wofsy C. B., Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1984 Apr;100(4):495–499. doi: 10.7326/0003-4819-100-4-495. [DOI] [PubMed] [Google Scholar]
  10. Grivsky E. M., Lee S., Sigel C. W., Duch D. S., Nichol C. A. Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine. J Med Chem. 1980 Mar;23(3):327–329. doi: 10.1021/jm00177a025. [DOI] [PubMed] [Google Scholar]
  11. Jackson P. R., Pappas M. G., Hansen B. D. Fluorogenic substrate detection of viable intracellular and extracellular pathogenic protozoa. Science. 1985 Jan 25;227(4685):435–438. doi: 10.1126/science.2578226. [DOI] [PubMed] [Google Scholar]
  12. Jaffe H. S., Abrams D. I., Ammann A. J., Lewis B. J., Golden J. A. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet. 1983 Nov 12;2(8359):1109–1111. doi: 10.1016/s0140-6736(83)90627-x. [DOI] [PubMed] [Google Scholar]
  13. Leoung G. S., Mills J., Hopewell P. C., Hughes W., Wofsy C. Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med. 1986 Jul;105(1):45–48. doi: 10.7326/0003-4819-105-1-45. [DOI] [PubMed] [Google Scholar]
  14. Lin J. T., Cashmore A. R., Baker M., Dreyer R. N., Ernstoff M., Marsh J. C., Bertino J. R., Whitfield L. R., Delap R., Grillo-Lopez A. Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics. Cancer Res. 1987 Jan 15;47(2):609–616. [PubMed] [Google Scholar]
  15. Pearson R. D., Hewlett E. L. Pentamidine for the treatment of Pneumocystis carinii pneumonia and other protozoal diseases. Ann Intern Med. 1985 Nov;103(5):782–786. doi: 10.7326/0003-4819-103-5-782. [DOI] [PubMed] [Google Scholar]
  16. Sjoerdsma A., Golden J. A., Schechter P. J., Barlow J. L., Santi D. V. Successful treatment of lethal protozoal infections with the ornithine decarboxylase inhibitor, alpha-difluoromethylornithine. Trans Assoc Am Physicians. 1984;97:70–79. [PubMed] [Google Scholar]
  17. Weir E. C., Cashmore A. R., Dreyer R. N., Graham M. L., Hsiao N., Moroson B. A., Sawicki W. L., Bertino J. R. Pharmacology and toxicity of a potent "nonclassical" 2,4-diamino quinazoline folate antagonist, trimetrexate, in normal dogs. Cancer Res. 1982 May;42(5):1696–1702. [PubMed] [Google Scholar]
  18. Young L. S. Management of opportunistic infections complicating the acquired immunodeficiency syndrome. Med Clin North Am. 1986 May;70(3):677–692. doi: 10.1016/s0025-7125(16)30946-4. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES